Clinical risk factors for portopulmonary hypertension†

Steven M. Kawut(Hospital of the University of Pennsylvania), Michael B. Fallon(University of Arizona), Neil Kaplowitz(University of Southern California), Evelyn M. Horn(Cornell University), David B. Badesch(University of Colorado Anschutz Medical Campus), Steven Zacks(University of North Carolina at Chapel Hill), Raymond L. Benza(Triangle), Darren B. Taichman(University of Pennsylvania), Robert S. Brown(Cornell University), Kari E. Roberts(Tufts Medical Center), James F. Trotter(Baylor Scott & White Health), Michael J. Krowka(Mayo Clinic)
Hepatology
March 19, 2008
10.1002/hep.22275
Cited by 286

Related Papers

Clinical Characteristics of Covid-19 in New York City
|New England Journal of Medicine|2020|2.4k
Efficacy and safety of a paired sedation and ventilator weaning protocol for mechanically ventilated patients in intensive care (Awakening and Breathing Controlled trial): a randomised controlled trial
|The Lancet|2008|2k
Definitions and Diagnosis of Pulmonary Hypertension
|Journal of the American College of Cardiology|2013|1.8k
Predicting Survival in Pulmonary Arterial Hypertension
|Circulation|2010|1.5k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k